JP2020520368A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520368A5
JP2020520368A5 JP2019563558A JP2019563558A JP2020520368A5 JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5 JP 2019563558 A JP2019563558 A JP 2019563558A JP 2019563558 A JP2019563558 A JP 2019563558A JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5
Authority
JP
Japan
Prior art keywords
composition
particles
cancer
poly
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/079688 external-priority patent/WO2018210439A1/en
Publication of JP2020520368A publication Critical patent/JP2020520368A/ja
Publication of JP2020520368A5 publication Critical patent/JP2020520368A5/ja
Priority to JP2022157413A priority Critical patent/JP2022188159A/ja
Priority to JP2024131720A priority patent/JP2024160312A/ja
Pending legal-status Critical Current

Links

JP2019563558A 2017-05-17 2017-11-17 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 Pending JP2020520368A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022157413A JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2024131720A JP2024160312A (ja) 2017-05-17 2024-08-08 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17171617 2017-05-17
EP17171617.8 2017-05-17
EP17382301 2017-05-26
EP17382301.4 2017-05-26
EP17200469.9 2017-11-07
EP17200469 2017-11-07
PCT/EP2017/079688 WO2018210439A1 (en) 2017-05-17 2017-11-17 Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022157413A Division JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Publications (2)

Publication Number Publication Date
JP2020520368A JP2020520368A (ja) 2020-07-09
JP2020520368A5 true JP2020520368A5 (OSRAM) 2021-01-07

Family

ID=64273459

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019563558A Pending JP2020520368A (ja) 2017-05-17 2017-11-17 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2022157413A Pending JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2024131720A Pending JP2024160312A (ja) 2017-05-17 2024-08-08 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022157413A Pending JP2022188159A (ja) 2017-05-17 2022-09-30 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
JP2024131720A Pending JP2024160312A (ja) 2017-05-17 2024-08-08 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物

Country Status (10)

Country Link
US (6) US10849921B2 (OSRAM)
EP (2) EP3448363B1 (OSRAM)
JP (3) JP2020520368A (OSRAM)
CN (2) CN110831581A (OSRAM)
AU (2) AU2017414660A1 (OSRAM)
CA (1) CA3063805C (OSRAM)
DK (1) DK3448363T3 (OSRAM)
ES (1) ES2924138T3 (OSRAM)
PL (1) PL3448363T3 (OSRAM)
WO (1) WO2018210439A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102317281B1 (ko) * 2015-11-17 2021-10-25 하이라이트 테라퓨틱스 에스.엘. 이본쇄 폴리리보뉴클레오타이드 및 폴리알킬렌이민의 복합체를 포함하는 입자를 포함하는 신규 약제학적 조성물
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
WO2020072366A1 (en) * 2018-10-01 2020-04-09 The Regents Of The University Of California Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy
WO2020077077A1 (en) * 2018-10-10 2020-04-16 The Regents Of The University Of California Combination immunotherapies
EP4603098A3 (en) 2018-11-01 2025-09-03 Alpha Tau Medical Ltd. Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
US20210396737A1 (en) * 2018-11-21 2021-12-23 Highlight Therapeutics, S.L. Nanoplexed poly(i:c) formulations and uses thereof
PY2265694A (es) * 2021-07-30 2023-03-08 Salazar Andres Actividad biologica multidimensional optimizada de poli-iclc con tamaño y formulacion de componentes controlados
CN114525253B (zh) * 2022-03-09 2024-03-15 南开大学 一种脂多糖诱导的外泌体及其应用
US20240091348A1 (en) 2022-09-20 2024-03-21 Highlight Therapeutics, S.L. Novel compositions based on polyinosinic-polycytidylic acid

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194002C (zh) * 1999-02-15 2005-03-23 日本新药株式会社 短链化多核苷酸及其制备方法
WO2005102278A1 (en) 2002-07-03 2005-11-03 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
US7927792B2 (en) 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
JP4861036B2 (ja) 2006-03-31 2012-01-25 リンテック株式会社 剥離シートおよびその製造方法
WO2008057696A2 (en) 2006-10-10 2008-05-15 Juvaris Biotherapeutics, Inc. Compositions of pattern recognition receptor-ligand: lipid complexes and methods of use thereof
KR100958293B1 (ko) 2008-03-27 2010-05-19 단국대학교 산학협력단 테오필린에 의해 표적 특이적 ｒｎａ 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 ｉ 리보자임
WO2009130301A1 (en) * 2008-04-25 2009-10-29 Institut Gustave Roussy Improved treatment of cancer using tlr3 agonists in combination with another therapeutic agent
MX2011006720A (es) * 2008-12-22 2011-10-06 Yissum Res Dev Co Vector de acido ribonucleico de cadena doble buscador del receptor del factor de crecimiento epidermico para el tratamiento sistemico del cancer.
ES2368963B1 (es) * 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
CN102988303A (zh) 2011-09-15 2013-03-27 天津泽世德生物医药有限公司 一种多聚肌苷酸多聚胞苷酸冻干粉针的制备方法
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
WO2013063019A1 (en) 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
WO2013087083A1 (en) * 2011-12-15 2013-06-20 Biontech Ag Particles comprising single stranded rna and double stranded rna for immunomodulation
BR112014026957A8 (pt) 2012-05-03 2018-01-16 Janssen R&D Ireland micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
WO2014165296A1 (en) 2013-03-12 2014-10-09 Multicell Immunotherapeutics, Inc. Methods and formulations to achieve tumor targeted double stranded rna mediated cell death
RU2016117398A (ru) * 2013-11-06 2017-12-11 Янссен Сайенсиз Айрлэнд Юси Композиции полиинозиновой-полицитидиловой кислоты (поли (и:ц)) для лечения инфекций верхних дыхательных путей
CN103599071B (zh) 2013-11-08 2016-01-27 杭州美亚药业股份有限公司 一种双链聚肌胞干粉的制备方法
SG10201911695SA (en) 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
JP2018515479A (ja) * 2015-05-05 2018-06-14 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法
KR102317281B1 (ko) * 2015-11-17 2021-10-25 하이라이트 테라퓨틱스 에스.엘. 이본쇄 폴리리보뉴클레오타이드 및 폴리알킬렌이민의 복합체를 포함하는 입자를 포함하는 신규 약제학적 조성물
CA3025812A1 (en) 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
US10849921B2 (en) * 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Similar Documents

Publication Publication Date Title
Han et al. Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer
Ying et al. Macrophage membrane-biomimetic adhesive polycaprolactone nanocamptothecin for improving cancer-targeting efficiency and impairing metastasis
Li et al. Nanotechnology: breaking the current treatment limits of lung cancer
Shen et al. Alendronate triggered dual‐cascade targeting prodrug nanoparticles for enhanced tumor penetration and STING activation of osteosarcoma
Ban et al. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy
Zhou et al. Nanoparticle‐mediated STING agonist delivery for enhanced cancer immunotherapy
Guorgui et al. Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice
Wang et al. Endogenous stimuli‐activatable nanomedicine for immune theranostics for cancer
Norouzi et al. Injectable hydrogel-based drug delivery systems for local cancer therapy
Bauleth‐Ramos et al. Acetalated dextran nanoparticles loaded into an injectable alginate cryogel for combined chemotherapy and cancer vaccination
Zhang et al. Metal coordination‐driven assembly of stimulator of interferon genes‐activating nanoparticles for tumor chemo‐immunotherapy
Talelli et al. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Yu et al. Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer
Chen et al. iRGD tumor-penetrating peptide-modified nano-delivery system based on a marine sulfated polysaccharide for enhanced anti-tumor efficiency against breast cancer
US10632081B2 (en) Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis
Wu et al. Promote intratumoral drug release and penetration to counteract docetaxel‐induced metastasis by photosensitizer‐modified red blood cell membrane‐coated nanoparticle
Wang et al. Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: a comparative study of molecular inhibitors and siRNA therapeutics
Wang et al. Polysaccharide nanodonuts for photochemotherapy‐amplified immunogenic cell death to potentiate systemic antitumor immunity against hepatocellular carcinoma
Mollica et al. Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer
Li et al. EGF‐functionalized lipid–polymer hybrid nanoparticles of 5‐fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma
Jiang et al. Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity
Kazemi et al. PNA-ATP aptamer-capped doxorubicin-loaded silica nanoparticles for targeted cancer therapy
Jia et al. Radioiodine‐131‐Labeled theranostic nanoparticles for transarterial radioembolization and chemoembolization combination therapy of VX2 liver tumor
Fu et al. Peptide modified albumin–paclitaxel nanoparticles for improving chemotherapy and preventing metastasis
Zhu et al. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis